Cite
HARVARD Citation
Nash, P. et al. (n.d.). SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study. Annals of the rheumatic diseases. pp. 1010-1011. [Online].